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Abstract 
Primary mucinous cystadenocarcinoma (MCA) of the breast was first described by Koenig 
and Tavassoli in 1998. To our knowledge, only 9 cases of MCA of the breast have been 
reported. The optimal treatment of MCA could not be defined yet. This article aims to 
increase the knowledge about this rare variant of breast cancer and to review the 
literature. 
 
Introduction 
Mucinous cystadenocarcinoma (MCA) is a very rare tumor of the breast. In the 
literature, only a handful of cases have been reported [1]. These tumors are a rare, 
clinicopathologically distinct type of primary breast carcinoma that should be 
distinguished from typical mucinous (colloid) carcinomas of the breast and, more 
importantly, metastases from other sites such as the pancreas and ovaries [2–4]. 
Case Report 
A 52-year-old premenopausal woman presented with a mass in her left breast. There were neither 
nipple discharge nor skin retraction. She has no children and no history of hormonal treatment or 
tumor history in the family. Physical examination revealed a big firm tumor of 5 × 10 cm in size in the  
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breast. No axillary lymph node involvement was noticed. Mammography showed a well-defined 
multilobular mass in the left breast involving nearly the whole breast. The tumor was well-defined and 
had neither spiculated margins nor intralesional microcalcification (fig. 1). 
Fine-needle aspiration biopsy revealed a benign mass that had suspicious malignant findings. 
Therefore, an excisional biopsy was performed. Gross inspection revealed a grey, gelatinous, 
multilocular cystic tumor containing mucinous material with some necrosis. Microscopically, variably 
sized cystic spaces were observed. The tumor was confined with atypical cells containing 
intracytoplasmic mucin (fig. 2). Also extracellular mucin was present in the tumor (fig. 3). 
The tumor was diagnosed as mucinous cystadenocarcinoma (MCA). After this diagnosis, an 
abdominopelvic ultrasonography was performed and proved to be normal. There was no pathology in 
the ovaries and pancreas. Modified radical mastectomy was performed. There was residual tumor in the 
specimen and tumor in the nipple, but no skin infiltration. The specimen had atypical ductal 
hyperplasia. In the axillary dissection material, there were 10 reactive lymph nodes. 
Immunohistochemically, the tumor cells were positive for estrogen receptor (ER; 95%) (fig. 4), and 
completely negative for progesterone receptor (PR) and C-erb-B2 receptor. Also cytokeratin 7 (CK7), 20 
(CK20), and chromogranin immunoreactivities were negative. 
According to the American Joint Committee on Cancer Staging System [6], the tumor was staged as 
Stage IIA (T3N0M0). Because of ER positivity, tamoxifen was given. The patient has been followed for 
24 months without chemotherapy (CT) and radiotherapy (RT) and has no metastasis or recurrence. 
Discussion 
Mucin-producing breast carcinomas have been broadly categorized into mucinous 
carcinoma, in which malignant cells are suspended in extracellular mucin, and signet ring 
cell carcinoma, in which the mucin is predominantly intracellular. Primary MCA of the 
breast, however, demonstrates both intracellular and extracellular mucin and is 
histologically similar to primary MCA of the pancreas and ovary [7]. It may be 
misinterpreted as a benign lesion because the small biopsy specimens may only consist of 
tumor cells with bland nuclei [8]. This case is the 10th case of breast MCA. In the 
literature, all the known MCA cases showed loss of ER and PR expression, but this case 
shows that MCA can also be ER-positive. According to the literature, the prognosis seems 
good even in tumors with a size of 10 cm [8].  
Ovary and pancreas mucinous adenocarcinoma are usually CK7+/CK20+, while MCA 
of the breast is usually CK7+ and CK20–. The antibody panel including CK7 and CK20 
may be useful to make a differential diagnosis between primary and metastatic mucinous 
tumors, but detailed clinical evaluation is necessary [8]. Neuroendocrine differentiation 
with expression of chromogranin is frequently demonstrated in mucinous carcinoma, but 
not in all MCAs nor in our case [8]. 
The MCAs of the breast in the literature, including the present case, are presented in 
table 1. Notably, in the 9th case reported in the literature, too, both ER and PR in the 
primary MCA of the breast were negative, whereas ER and PR in the MCA were often 
expressed [10]. Since the MCAs were ER- and PR-negative, the hypothesis can be made 
that these tumors have been developed free from estrogen stimulation [5]. Therefore, no 
patients received hormonotherapy. The fact that our case was stained highly ER-positive 
led to the idea that these tumors are also estrogen-sensitive, as the other primary breast 
tumors. Therefore, when determining the treatment of patients presenting with this kind 
of tumor, hormonotherapy should also be considered as an option. This inhibits both 
translocation and nuclear binding of tamoxifen receptor, thereby preventing estrogen 
responsive genes from transcriptional activation. Tamoxifen induces apoptosis and 
prevents tumor growth, protein inhibits kinases and provides the regulation of tumor 
growth factors [11, 12]. Moreover, insulin growth factor affects regulatory cytokines such  
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as TGFβ, and basic fibroblast growth factor inhibits angiogenesis [13]. In in vivo studies, 
it was determined that the level of VEGF that has an impact on angiogenesis was also 
decreased [13–15]. We hoped that tamoxifen would be effective in our patient 
considering all the mechanisms mentioned above. ER, PR and c-erb-B2 is stained 
negative in MCA [5, 8]. Our case was stained ER-positive and PR- and c-erb-B2-negative. 
As it is known, ER, PR and c-erb-B2 triple negative breast tumors are associated with 
poor prognosis [16]. Indeed, it could be expected that the receptors of these tumors, 
which are nonmetastatic, without local recurrence and with good prognosis, would be 
positive. 
Patients were between 47 and 96 years old and older patients were likely to develop 
MCA [5, 8]. Patients were often postmenopausal and the age of average incidence was 68 
[8]. Our patient was also postmenopausal. 
MCA was noted to originate from the main ductus close to the papilla [5, 8]. Papilla 
involvement in the mammographic images and histopathological investigation in our case 
also supported this hypothesis. 
Out of 10 patients, 2 developed lymph node metastasis, which is considered to be 
associated with the long history of the primary tumor [2, 5]. Our patient had a short 
history and presented with no axillary lymph node metastasis. Honma et al. [5] treated a 
patient presenting with a 6-cm conglomerate of axillary metastatic lymph nodes with 
mastectomy (M) and lymph node dissection (LND), and after 46 months of follow-up 
without adjuvant therapy, the patient died from a disease other than MCA. These facts 
lead to the assumption that axillary lymph node metastasis is not associated with poor 
prognosis. 
The general treatments were M and LND; however, 3 patients underwent lumpectomy. 
With respect to postoperative adjuvant therapy, 1 patient [2] received RT, while 2 patients 
[2, 8] received CT. In the study of Koenig and Tavassoli [2], a third case presenting with a 
8.5-cm diameter sarcomatous component was exposed to adjuvant CT and RT after M 
and LND. The CT given to this patient was a combination including antracyclin, which 
seems logical as it included a sarcomatous component. This patient presented with no 
disease during an 11-month follow-up. The second patient [8] receiving CT in the 
literature was the one presenting with a 3-cm diameter tumor but no nodal metastasis, 
and undergoing M and LND. RT indication was not suggested when the patient was 
assessed for RT to the chest wall. 
In the literature, a patient presenting with a 19-cm tumor and lymph node metastasis 
was treated with M and LND, but did not receive CT and RT [2]. If the case had been 
assessed classically, as the other invasive breast cancer types, this patient would have been 
delivered RT and CT. However, during a 24-month follow-up, no disease was observed in 
the patient. The other patient presenting with lymph node metastasis [5] and with a 2-cm 
diameter tumor was treated with lumpectomy and LND, but did not receive RT and CT, 
and the patient died from a disease other than MCA at the end of a 46-month follow-up. 
This contributes to the hypothesis that surgery is indeed sufficient for the treatment of 
this disease. In the study of Rosen et al. [3], the patient presenting with a 6-cm diameter 
tumor and undergoing mastectomy and LND, but not receiving adjuvant therapy, did not 
experience any symptoms related to this disease in a 9-year follow-up. 
As indicated in table 1, for the 4th, 6th and 9th patients undergoing breast-conserving 
surgery, for the first patient presenting with a 19-cm diameter tumor, and for the patients 
presenting with metastatic axillary lymph nodes [3, 8] RT was not suggested. None of  
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these patients developed locoregional recurrence, and therefore, we should pay attention 
when suggesting RT for these patients. Compatible with this, in the light of current 
literature we did not suggest CT and RT for our patients. Because ER was highly positive 
in our patient and because we found invasive atypical epithelial hyperplasia, tamoxifen 
was started. 
Although it is not sufficient to discuss only a few patients with good prognosis of these 
rare breast tumors, it can be seen that the patients were not affected by CT and RT. No 
recurrence or death related to disease occurred in any of the patients [8]. The follow-up 
period reported was 9 years at the most and 8 months at least. Although the nature of 
breast MCAs is invasive, these carcinomas are associated with a good prognosis [7]. 
However, it is necessary to differentiate primary MCA of the breast from other benign 
lesions of the breast releasing the typical mucin and mucinous carcinoma [5, 7, 8]. More 
importantly, it is necessary to conduct detailed clinical and histopathological 
investigations in order to differentiate the organs in the abdomen and pelvis from MCA 
metastases in the pancreas and ovaries [2, 5, 8]. 
In conclusion, we need to observe a certain disease progression and therefore more 
cases to answer the question whether only surgery or, as in other invasive breast tumors, a 
combination of surgery, CT and RT is to be used for the treatment of this rare breast 
cancer with good prognosis.  
 
 
 
Table 1. Summary of clinicopathologic features 
Case  
No. 
R  Age  Tumor 
size, cm 
LNM  Treatment  Follow-up  ER  PR  CK7  CK20 
1  2  54  19.0  +  M, LND  24 months
a –  –  +  – 
2  2  67  02.3  –  M, LND  22 months
a –  –  +  – 
3  2  49  08.5  –  M, LND, CT, RT  11 months
a –  –  +  – 
4  2  61  00.8  –  Lumpectomy, LND 
b  –  –  +  – 
5  4  74  10  –  M, LND  02 years
a  –  –  +  – 
6  5  96  02.0  +  Lumpectomy, LND  46 months* –  –  +  – 
7  3  79  06.0  –  M, LND  09 years*  –  –  +  – 
8  8  65  03.0  –  M, LND, CT  08 months
a –  –  +  rare 
9  7  51  04.0  –  Lumpectomy 
b  –  –  +  – 
Present case    52  10.0  –  M, LND, TMX  24 months
a +  –  –  – 
LNM = Lymph node metastasis; M = mastectomy; LND = lymph node dissection; CT = chemotherapy;
RT = radiation therapy; TMX = tamoxifen. 
a Alive with no evidence of disease; 
b unknown. * Died of 
disease other than MCA. 
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Fig. 1. Mediolateral oblique mammographic graphs of the left breast: a well defined multilobular mass 
involving the whole breast which has neither spiculated margins nor intralesional microcalcification. 
 
 
 
Fig. 2. The extracellular free mucin in the tumor. ×100. HE. 
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Fig. 3. The intracytoplasmic mucin in the tumor. 
 
 
 
Fig. 4. Tumor of cells positive for estrogen receptor. ×400. 
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